Clinical dissection of thrombotic microangiopathy

被引:0
作者
Eunjeong Kang
Shin Hye Yoo
Doyeun Oh
Kwon Wook Joo
Yon Su Kim
Sung-Soo Yoon
Inho Kim
Seonyang Park
Hajeong Lee
Youngil Koh
机构
[1] Seoul National University College of Medicine,Department of Internal Medicine
[2] CHA University School of Medicine,Division of Hematology
[3] Seoul National University College of Medicine,oncology, Department of Internal Medicine
[4] Seoul National University College of Medicine,Division of Nephrology, Department of Internal Medicine
[5] Seoul National University College of Medicine,Kidney Research Institute
来源
Annals of Hematology | 2017年 / 96卷
关键词
Thrombotic microangiopathy; Clinical manifestation; Hemolytic uremic syndrome;
D O I
暂无
中图分类号
学科分类号
摘要
Differential treatment strategies are applied in thrombotic microangiopathy (TMA) according to the sub-classifications. Hence, it is worthwhile to overview clinical manifestations and outcomes of overall TMA patients according to sub-classifications. We analyzed TMA patients whose serum lactate dehydrogenase levels >250 IU/L, with the presence of schistocytes in their peripheral blood smear, or with typical vascular pathologic abnormalities in their renal biopsy. We compared clinical manifestations including overall survival (OS) and renal survival according to TMA causes. A total of 117 TMA patients (57 primary and 60 secondary TMA) were analyzed. Renal symptom was the most common manifestation in whole patients, while renal function at diagnosis was worst in pregnancy-related TMA group. Primary TMA patients had more frequent CNS symptom and hematologic manifestation compared to secondary TMAs. Among secondary TMAs, pregnancy- and HSCT-related TMA patients showed prevalent hemolytic features. During 150.2 months of follow-up, 5-year OS rate was 64.8%. Poor prognostic factors included older age, combined hematologic and solid organ malignancies, lower hemoglobin levels, and lower serum albumin levels. There was no significant difference in OS between primary and secondary TMAs. Seventy-eight percent of patients experienced AKI during TMA. Five-year death-censored renal survival rate was poor with only 69.2%. However, excellent renal outcome was observed in pregnancy-associated TMA. TMA showed various clinical manifestations according to their etiology. Notably, both OS and renal survival were poor regardless of their etiologies except pregnancy-associated TMA. Physicians should differentiate a variety of TMA categories and properly manage this complex disease entity.
引用
收藏
页码:1715 / 1726
页数:11
相关论文
共 99 条
[31]  
Eremina V(2012)Predicting progression of IgA nephropathy: new clinical progression risk score PLoS One 7 132-2326
[32]  
Cui S(2015)Lessons from 30 years’ data of Korean end-stage renal disease registry, 1985-2015 Kidney Res Clin Pract 34 2323-362
[33]  
Gerber H(2012)Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome Pediatr Nephrol 27 357-609
[34]  
Markowitz GS(2016)Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: a single center experience from Turkey Transfus Apher Sci 55 604-439
[35]  
Bomback AS(2012)Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes Hematol Am Soc Hematol Educ Program 2012 437-undefined
[36]  
Perazella MA(2006)A case of hemolytic uremic syndrome caused by Yonsei Med J 47 undefined-undefined
[37]  
Noris M(undefined) O104:H4 undefined undefined undefined-undefined
[38]  
Remuzzi G(undefined)undefined undefined undefined undefined-undefined
[39]  
Kavanagh D(undefined)undefined undefined undefined undefined-undefined
[40]  
Goodship TH(undefined)undefined undefined undefined undefined-undefined